Entrada Therapeutics (TRDA) Interest Expenses (2020 - 2026)

Entrada Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $18000.0 for Q1 2026.

• On a quarterly basis, Interest Expenses fell 86.57% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was $18000.0, a 86.57% decrease from a year earlier, with the FY2025 full-year figure at $12.7 million, down 79.89% from the prior year.
• Interest Expenses held at $18000.0 in Q1 2026 per TRDA's latest filing, from $18000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $102.4 million in Q2 2023 and bottomed at -$13.2 million in Q4 2023.
• The 5-year median for Interest Expenses is $317500.0 (2024), against an average of $16.1 million.
• Across the five-year window, Interest Expenses plunged 134.82% in 2023 and jumped 578.11% in 2024, its largest moves.
• Year by year, Interest Expenses stood at -$5.6 million in 2022, then plunged by 134.82% to -$13.2 million in 2023, then soared by 578.11% to $62.9 million in 2024, then plunged by 99.97% to $18000.0 in 2025, then changed by 0.0% to $18000.0 in 2026.
• Per Business Quant, the three latest TRDA Interest Expenses figures stand at $18000.0 (Q1 2026), $18000.0 (Q3 2025), and $114000.0 (Q2 2025).